These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 16857827

  • 1. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
    Johnson DH.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J.
    J Natl Compr Canc Netw; 2003 Jan 15; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA, Lynch TJ.
    Oncologist; 2009 Apr 15; 14(4):399-411. PubMed ID: 19357226
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD.
    Curr Opin Oncol; 2006 Nov 15; 18(6):609-14. PubMed ID: 16988582
    [Abstract] [Full Text] [Related]

  • 9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD, Buckingham L, Coon J.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV, Bell DW, Settleman J, Haber DA.
    Nat Rev Cancer; 2007 Mar 01; 7(3):169-81. PubMed ID: 17318210
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
    Belani CP.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 14):25-33. PubMed ID: 15726531
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
    Krause M, Gurtner K, Deuse Y, Baumann M.
    Int J Radiat Biol; 2009 Nov 01; 85(11):943-54. PubMed ID: 19895271
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Methodology for the assessment of new targeted treatments in clinical trials. Future perspectives].
    Quoix E.
    Rev Pneumol Clin; 2004 Nov 01; 60(5 Pt 2):3S72-8. PubMed ID: 15536358
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.